Mylan: pen is not mightier

©Epipen Media Room

Drug group has yet to justify the pricing on Epipen

Brexit: apocalypse, no

If the sky fell, and people ignored it, has the sky really fallen?

South32: low roller

The company has the cash to pay its shareholders much more

Japan governance: holding patterns

Knowing who owns which shares has never been more important

HP Inc: Keep on printing

There is life in the old hardware unit yet

SCA group: not a page turner

How separated divisions works out is an open question

Glencore: feather in his cap

Chief executive Ivan Glasenberg buckles down on debt

WPP: sunny days

The advertising group deserves more of a premium valuation

Australian food retail: no more goodwill

The winner is merely the best of two losers

Fitbit: bearable wearable

Legal ruling is a boost but the path ahead will have obstacles